Effects of Tranexamic Acid

Joseph F. Rappold, MD FACS
CAPT MC USN (Ret)
Department of Surgery
Temple University School of Medicine
“Medicine is a science of uncertainty and an art of probability”

Sir William Osler
Response to Surgery and Injury

- Surgery and trauma results in stimulation of clot breakdown (fibrinolysis) which can become pathological (hyper-fibrinolysis)
- Most believe that this is through a Protein C mediated pathway and activation of fibrinolysis

Response to Surgery and Injury

- Anti-fibrinolytic agents (TXA) can reduce blood loss in patients with both normal and exaggerated fibrinolytic responses to surgery and trauma without increasing the risk of post-operative or post-injury complications.
TXA – Mechanism of Action

• TXA is a synthetic derivative of lysine that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen
TXA – Pharmacology

• Anti-fibrinolytic that inhibits both Plasminogen activation and Plasmin activity thus preventing clot breakdown rather than promoting new clot formation

• 10x more potent (in vitro) than Aminocaproic acid
TXA – Pharmacokinetics

- **Absorption** –
  - Onset of action: 5-15 minutes
  - Duration: 3 hours

- **Distribution** –
  - Protein binding ~ 3%; primarily to Plasminogen

- **Metabolism** –
  - T1/2: 2-11 hours

- **Excretion** –
  - Urine (>95% as unchanged drug)
TXA – Dosing/Storage

- TXA (Cyklokapron) – 1gm in 100cc/NSS given over 10 minutes (loading dose)
  - Followed by 1gm in 100cc/NSS over 8 hrs
- Can be mixed with just about any available solution
- Not to be administered in the same line as blood or blood products or in a line used for rFVIIa or Penicillin
- Should be stored between 15-30C or 56-86F
TXA – Side Effects

• Ocular – color vision change, vision loss
• Seizure – probably related to neuronal GABA inhibition
• Renal Impairment
• Ureteral Obstruction – upper tract obstruction may lead to bleeding
TXA - Contraindications

• Acquired defective color vision
• SAH
• Active intravascular clotting
• Hypersensitivity to TXA
Data – CRASH 2

• CRASH -2:
  – Randomized, prospective study
  – 247 hospitals, 40 countries, 20211 included
  – Primary outcome was death at 4 weeks with intention to treat
  – All cause mortality decreased by 10% (RR 0.91, 95% CI 0.85-0.97)
  – Risk of death from bleeding decreased by 15% (RR 0.85, 95% CI 0.76-0.96)
Data – MATTERs Study

• Retrospective, observational trial
  – Compared TXA administration with non-TXA administration in combat casualties receiving at least 1u pRBC. A subset of patients receiving a massive transfusion was also analyzed
  – 896 consecutive patients with combat casualties of which 293 received TXA
  – TXA group had lower unadjusted mortality (17.4% vs. 23.9%; P=0.3); benefit greater in patients receiving MT (14.4% vs. 28.1%; P=.04); TXA independently associated with survival (OR=7.7228; CI 3.016-17.322)
Data – Meta Analysis

• BMJ May 2012 (K Ker et al.)
• 129 Trials; 10488 patients, reduced the probability of receiving a blood transfusion by a third (risk ratio 0.62, 95% confidence interval 0.59 to 0.65; P<0.001)
• Fewer deaths in TXA group (0.61, 0.38 to 0.98; P=0.04)
  – Statistical concerns about this group
Final Thoughts

• TXA is a highly valuable adjunct that can improved survival from hemorrhage secondary to trauma
• Still some basic science questions outstanding and in the process of being answered
• BOTTOM LINE – severe trauma - GIVE